Corcept Therapeutics Inc. vs Eli Lilly & Co.
CORT vs LLY — side-by-side comparison from reported financials. CORT leads 2, LLY leads 9 of 11 comparable metrics.
Corcept Therapeutics Inc.
CORT · Healthcare
$121.19+2.24%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | CORT | LLY |
|---|---|---|
| Price | $121.19 | $1 177.20 |
| Market cap | $13.1B | $1.05T |
| Revenue (TTM) | $831M | $79.7B |
| Revenue growth | +23.7% | +31.7% |
| Net margin | 6.6% | 33.5% |
| Free cash flow | $107M | $18.2B |
| Net cash (debt) | $366M | ($35.2B) |
| 1-year price return | +37.2% | +37.6% |
| P/E | 237.4 | 41.6 |
| P/E vs own history (cheap-side %) | 0% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 8% | 93% |
| Altman Z-score | 44.76 | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 730 | 50,000 |
Full résumé-style profiles: CORT CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.